Impact of Immune Checkpoint Inhibitors on SCLC Chemotherapy
Findings from a meta-analysis revealed that adding immunotherapy to chemotherapy in patients with small cell lung cancer (SCLC) is correlated with a greater risk of toxicity and possibly termination of therapy. The study compared any grade treatment-related adverse events (TRAEs) and treatment discontinuation due to TRAEs between patients receiving front-line immune checkpoint inhibitors plus chemotherapy and those receiving chemotherapy alone. Read more.

Depression in NSCLC Patients Correlated With Elevated Inflammation
According to findings from a study, patients with non-small cell lung cancer (NSCLC) who also suffer from moderate-to-severe depression symptoms could be two to three times more likely to have elevated levels of inflammatory biomarkers, and the biomarkers may aid clinicians in predicting poorer clinical outcomes and survival rates. Learn more about the results of this study.

Postmenopausal Hormone Therapy Lowers Risk of Lung Cancer
The benefits and risks of hormone therapy (HT) have been debated among healthcare providers for the past 2 decades, and findings regarding the augmented risk of developing lung cancer have been inconsistent. According to findings from a study, the use of HT for menopause does not increase a woman’s risk—and may actually aid in lowering the risk—of developing lung cancer. Read more.